Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
Active, not recruiting
- Conditions
- Glaucoma, Open-Angle
- Registration Number
- NCT05159817
- Lead Sponsor
- Ciliatech
- Brief Summary
The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.
- Detailed Description
19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted.
These patients reached 6 months follow-up and the original study had to be interrupted.
This observational study prolonges follow-up to 36 months
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
- All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655
Exclusion Criteria
- if cannot assist to all future follow-up visits
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assess post-op IOP reduction 12, 24 and 36 months Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20%
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Malayan Center
🇦🇲Yerevan, Armenia